<DOC>
	<DOCNO>NCT02231359</DOCNO>
	<brief_summary>Tolerability , efficacy handle Berodual® Respimat® 20/50µg/dose solution inhalation patient chronic obstructive airway disease daily practice</brief_summary>
	<brief_title>Berodual® Respimat® Solution Inhalation Patients With Chronic Obstructive Airways Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Fenoterol , ipratropium drug combination</mesh_term>
	<mesh_term>Fenoterol</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<criteria>Men woman present symptom chronic obstructive airway disease give Berodual® Respimat® 20/50µg/dose solution inhalation consider necessary medical term Patients treat prior postmarketing surveillance study well patient treat Berodual® meter dose inhaler ( MDI ) respiratory medication prior PostMarketing Surveillance Study could include Patients present general specific contraindication list Patient Information Leaflet Basic Product Information</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>